Ethoxydol 100 mg 50 chewable tablets

The drug is indicated for use in adults.

• ischemic heart disease (as part of combination therapy);

• combination therapy for ischemic stroke;

• discircular encephalopathy;

• mild to moderate cognitive disorders.

Etoksidol® tablets are taken orally. The tablets should be chewed and swallowed with water. For the comprehensive therapy of ischemic heart disease and the treatment of ischemic stroke, the recommended dosage is 100 mg (1 tablet) three times a day, gradually increasing the dose until the therapeutic effect is achieved. The maximum single dose is 200 mg; the maximum daily dose is 800 mg.
The course of treatment should last at least 2 months, with repeat courses as recommended by a physician.
The duration of treatment and the selection of an individual dose depend on the severity of the patient's condition and the effectiveness of the treatment.
In the comprehensive therapy of mild to moderate cognitive disorders, the medication is prescribed without limitation on the duration of treatment at a dose of 100 mg 3-4 times a day.
Special patient groups
Elderly patients
Dose adjustment is not required.
Patients with liver failure
The medication is contraindicated in acute liver failure.
Patients with kidney failure
The medication is contraindicated in acute kidney failure.
Children
The medication is contraindicated for patients under 18 years of age. The safety and efficacy of the medication in children under 18 years have not been established. Data is unavailable.

One tablet contains:
active ingredient: ethylmethylhydroxypyridine succinate - 100 mg;
excipients: mannitol, glycine, crospovidone, aspartame, raspberry flavoring, magnesium stearate, sodium stearoyl fumarate, colloidal silicon dioxide.

Round flat-cylindrical tablets of white or almost white color, with a bevel and a score line, having a characteristic raspberry scent. "Marbling," speckles, and some roughness of the surface are acceptable.

Increased sensitivity to the components of the drug.
Acute liver and/or kidney failure, pregnancy, lactation period, age under 18 years (efficacy and safety not established).

This medication contains less than 1 mmol (23 mg) of sodium per tablet, essentially making it sodium-free.
This medication contains aspartame and may be harmful to individuals with phenylketonuria.

The frequency of adverse reactions is determined according to the following criteria: very common (≥1/10), common (≥1/100 but

Due to the low toxicity of the drug, overdose is unlikely. In case of accidental overdose, symptoms of sleep disturbance may occur - drowsiness, insomnia.
Symptomatic treatment is recommended.

Enhances the effects of antiepileptic agents (carbamazepine), antiparkinsonian agents (levodopa), and benzodiazepine anxiolytics. Increases the antianginal activity of nitro preparations and the hypotensive effects of ACE inhibitors and beta-blockers. Reduces the toxic effects of ethanol.

Ethoxydol® is an inhibitor of free radical processes, exhibiting membrane-protective, anti-hypoxic, nootropic, anticonvulsant, and anxiolytic effects, and increases the body's resistance to stress. Ethoxydol® possesses anti-ischemic properties, improves blood flow in the ischemic area, limits the zone of ischemic damage, demonstrates hypolipidemic action, and reduces total cholesterol and low-density lipoprotein levels. The drug enhances the body's resistance to various damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular disorders, alcohol intoxication, and antipsychotic agents (neuroleptics)). The drug improves brain metabolism and cerebral blood supply, enhances microcirculation and the rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. The mechanism of action of the drug is due to its antioxidant, anti-hypoxic, and membrane-protective effects. It inhibits lipid peroxidation, increases superoxide dismutase activity, enhances the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their binding capacity with ligands, contributes to the preservation of the structural-functional organization of biomembranes, and improves neurotransmitter transport and synaptic transmission.

After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract at an average rate of 0.569±0.086 h-1. In healthy volunteers, it was established that when 100 mg tablets of Ethoxydol® are taken orally, the maximum concentration (Cmax) in plasma is reached after 0.28±0.08 hours and is 487.0±72.4 ng/ml, followed by rapid elimination of the drug, with a half-life (T1/2) of 1.46±0.13 hours. Ethoxydol® is rapidly distributed throughout the organs and tissues of the body. It can be detected in plasma for 7-10 hours. The drug is intensively metabolized in the liver, resulting in the formation of phosphate-3-hydroxypyridine and glucuronoconjugated products.